Date published: 2025-12-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

ADAM18 Inhibitors

ADAM18 inhibitors are a class of chemical compounds designed to specifically inhibit the activity of ADAM18, a member of the ADAM (A Disintegrin And Metalloprotease) family of proteins. ADAM18 is involved in a variety of cellular processes, including proteolytic processing and cell-cell interactions, largely due to its metalloprotease and disintegrin domains. These domains enable ADAM18 to cleave other proteins and mediate binding with integrins or other cell surface receptors. Inhibitors of ADAM18 are typically designed to block the metalloprotease activity by binding to the catalytic zinc ion or by occupying the active site, thus preventing the enzyme from cleaving its substrates. These inhibitors often include functional groups that can interact with key residues in the active site, such as hydroxamate or sulfhydryl groups that chelate the zinc ion, as well as hydrophobic regions that interact with surrounding protein residues to stabilize the inhibitor-protein complex.

The development of ADAM18 inhibitors is guided by a detailed understanding of the protein's three-dimensional structure, particularly the configuration of its metalloprotease domain. Structural biology techniques such as X-ray crystallography or cryo-electron microscopy are used to elucidate the enzyme's active site, providing insights into the specific amino acids and zinc coordination that are critical for catalytic function. Based on this information, inhibitors are designed to fit precisely within the active site, disrupting substrate binding or enzymatic activity. Computational modeling tools, such as molecular docking and molecular dynamics simulations, are also used to predict and optimize the interactions between ADAM18 and potential inhibitors, improving their binding affinity and selectivity. Some inhibitors may also act allosterically by binding to regions outside the catalytic domain and inducing conformational changes that reduce ADAM18's activity. These inhibitors are important tools for studying the role of ADAM18 in proteolytic processes and cellular signaling, helping to explore the broader biological functions regulated by this metalloprotease within various cellular contexts.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Marimastat

154039-60-8sc-202223
sc-202223A
sc-202223B
sc-202223C
sc-202223E
5 mg
10 mg
25 mg
50 mg
400 mg
$165.00
$214.00
$396.00
$617.00
$4804.00
19
(1)

Broad-spectrum metalloproteinase inhibitor, could indirectly affect ADAM18 activity.

TAPI-2

187034-31-7sc-205851
sc-205851A
1 mg
5 mg
$280.00
$999.00
15
(1)

Inhibits ADAM family metalloproteases, could influence ADAM18 function.

GM 6001

142880-36-2sc-203979
sc-203979A
1 mg
5 mg
$75.00
$265.00
55
(1)

Metalloproteinase inhibitor, might indirectly affect ADAM18 activity.

Doxycycline-d6

564-25-0 unlabeledsc-218274
1 mg
$16500.00
(0)

Antibiotic with metalloproteinase inhibitory properties, could impact ADAM18 function.

PD 166866

192705-79-6sc-208154
5 mg
$300.00
1
(0)

Synthetic broad-spectrum metalloproteinase inhibitor, potentially affecting ADAM18.

Cilengitide

188968-51-6sc-507335
5 mg
$215.00
(0)

Selective inhibitor of αvβ3 and αvβ5 integrins, might impact cell adhesion processes involving ADAM18.